AR-V7 and treatment selection in advanced prostate cancer: are we there yet?

Castration-resistant prostate cancer (CRPC) remains a lethal disease, despite marked improvements in outcomes over the past decade with incorporation of novel androgen-receptor signaling inhibitors (ARSi), taxane-based chemotherapies, sipuleucel-T and radium-223 (1). However, treatment sequencing is still based on subjective clinical parameters and physician experience, which remains a major challenge. Moreover, despite the identification of several prognostic markers, prospectively validated biomarkers used for treatment selection (that may guide oncologists in choosing the right treatment option for their patients at the right time) are still lacking.